Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene
Pelerin, D.; Silvestre, R. M.; Jerusalem, Guyet al.
2002 • In Revue Médicale de Liège, 57 (12), p. 755-6
[en] Thromboembolic complications are well known side effects of treatment with tamoxifen in patients with breast cancer. The authors review the pathophysiology and the risk factors that increase the probability to develop these complications. The most appropriate treatment is discussed.
Disciplines :
Oncology
Author, co-author :
Pelerin, D.
Silvestre, R. M.
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Sautois, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Polus, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Language :
French
Title :
Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene
Alternative titles :
[en] How I Manage Patients Developing Thromboembolic Complications as a Result of Breast Cancer Treatment with Tamoxifen
Publication date :
December 2002
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Cutuli B, Petit JC, Fricker JP, et al. - Accidents thrombo-emboliques chez les patientes ménopausées sous traitement adjuvant par tamoxifène. Fréquence, facteurs de risque et possibilité de prévention. Bull Cancer, 1995, 82, 51-56.
Meier CR, Jick H. - Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol, 1998, 45, 608-612.
Ragaz J, Coldman A. - Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol, 1998, 16, 2018-2024.
Weitz IC, Israel VK, Liebman HA. - Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer, 1997, 79, 2024-2027.
Tisman G. - Thromboses after estrogen hormone replacement, progesterone or tamoxifen therapy in patients with elevated blood levels of homocysteine. Am J Hematol, 2001, 68, 135.
Pritchard KI, Paterson AH, Paul NA, et al. - Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized triai of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Triais Group Breast Cancer Site Group. J Clin Oncol, 1996, 14, 2731-2737.
Mannucci PM, Bettega D, Chantarangkul V, et al.- Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med, 1996, 156, 1806-1810.
Oberhoff C, Szymeczek J, Hoffmann O, et al. - Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat, 1998, 50, 73-81.
Blann AD, Baildam AD, Howell A, Miller JP. - Tamoxifen increases von Willebrand factor in women who underwent breast cancer surgery. Thromb Haemost, 2001, 85, 941-942.
Deshmukh N, Tripathi SP. - Thrombosis of tibial arteries in a patient receiving tamoxifen therapy. Cancer, 1995, 76, 1006-1008.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359, 2131-2139.
